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Background: The ICOS-B7h costimulatory receptor-ligand pair is required for germinal center formation, the
production of isotype-switched antibodies, and antibody affinity maturation in response to T cell-dependent
antigens. However, the potentially distinct roles of regulated B7h expression on B cells and dendritic cells in
T cell-dependent antibody responses have not been defined.
Results: We generated transgenic mice with lineage-restricted B7h expression to assess the cell-type specific roles
of B7h expression on B cells and dendritic cells in regulating T cell-dependent antibody responses. Our results show
that endogenous B7h expression is reduced on B cells after activation in vitro and is also reduced in vivo on
antibody-secreting plasma B cells in comparison to both naïve and germinal center B cells from which they are
derived. Increasing the level of B7h expression on activated and plasma B cells in B-B7hTg mice led to an increase
in the number of antibody-secreting plasma cells generated after immunization and a corresponding increase in
the concentration of antigen-specific high affinity serum IgG antibodies of all isotypes, without affecting the
number of responding germinal center B cells. In contrast, ICOS costimulation mediated by dendritic cells in
DC-B7hTg mice contributed to germinal center formation and selectively increased IgG2a production without
affecting the overall magnitude of antibody responses.
Conclusions: Using transgenic mice with lineage-restricted B7h expression, we have revealed distinct roles of ICOS
costimulation mediated by dendritic cells and B cells in the regulation of T cell-dependent antibody responses.
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ICOS is an inducible costimulatory receptor expressed
on activated T cells that is a member of the CD28-B7
family of costimulatory molecules [1-4]. ICOS binds to
the ligand B7h [5] (also known as LICOS [6], ICOSL [7],
GL50 [8], B7RP-1 [9], and B7-H2 [10]), expressed consti-
tutively on the cell surface of resting B cells and dendritic
cells (DCs) [5,9,11,12], both of which can regulate T cell-
dependent antibody responses. Studies of B7h−/−and
ICOS−/− mice have demonstrated the requirement of the
ICOS-B7h receptor-ligand pair in germinal center* Correspondence: kevinlarimore@gmail.com
Immunology Division, Department of Molecular and Cell Biology, University
of California, Berkeley, CA 94720-3200 USA
© 2012 Larimore et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orformation, class switched antibody production and anti-
body affinity maturation [7,13-15], but the potentially
distinct roles of ICOS costimulation mediated by B7h-
expressing B cells and DCs in the regulation of antibody
responses have not been well defined.
ICOS signaling can promote IL-4 production, leading
to Th2 polarization of differentiating CD4+ T cells
[16,17], but can also enhance production of a variety of
cytokines in other Th subsets that have already differen-
tiated, including augmentation of IFN-γ production in
Th1 cells [18-20]. Thus, ICOS signaling in T cells can
have different effects on immune responses depending
upon the cellular context of ICOS-B7h interactions. In
T cell-dependent antibody responses, ICOS-expressingal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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expressing antigen presenting cells in several distinct
contexts, with the potential for regulation of different
aspects of the response through ICOS signaling during
each interaction. DCs can contact recently-activated
CD4+ ICOS+T cells in T cell zones [21], and DCs in ger-
minal centers can interact with ICOS+Tfh cells [22]. Re-
cently activated B cells interact with cognate activated
CD4+ T cells at the border of the T cell and B cell zones
in lymph nodes and spleen prior to germinal center and
plasma cell formation [22], germinal center B cells inter-
act with ICOS+ follicular helper T (Tfh) cells [23], and
antibody-secreting plasma B cells interact with activated
Th cells in periarteriolar lymphoid sheaths [24]. Because
the outcome of ICOS signaling in CD4+ T cells depends
upon the differentiation and programming of T cells in
each context [25], these interactions represent poten-
tially distinct points of control for antibody responses,
where modulation of ICOS signaling by regulated B7h
expression on antigen presenting cells could have differ-
ent effects.
Previous in vitro studies have shown that down-
regulation of B7h expression on B cells after activation
can restrict ICOS costimulation in cognate CD4+ T cells,
suggesting that regulation of B7h levels on activated B
cells in vivo could be a control mechanism in T cell-
dependent antibody responses. B7h expression on acti-
vated B cells is transcriptionally extinguished by expos-
ure to antigen and IL-4 [26], and is also limited by rapid
ectodomain shedding induced either by binding to ICOS
or by antigen receptor signaling [27]. Conversely, B7h
expression can be restored by the reactivation of tran-
scription induced by CD40 signaling [26], and enhanced
by the inhibition of ectodomain shedding induced by
TLR7/8 and TLR9 signaling [27]. Thus, the level of B7h
expression on activated B cells reflects the integration of
multiple critical B cell signaling pathways.
To investigate the cell type-specific functions of regu-
lated B7h expression on B cells and DCs in vivo, we gen-
erated transgenic mice with lineage-restricted B7h
expression. Our results show that ICOS costimulation
mediated by DCs contributes to germinal center forma-
tion in response to T cell-dependent antigens and leads
to a selective increase in antibody class switching to the
IgG2a isotype, without affecting the overall magnitude of
antibody responses. In contrast, increased expression of
B7h on B cells, but not on dendritic cells, markedly
enhances both the number of plasma cells secreting
antigen-specific high affinity class-switched antibodies
and the serum concentration of such antibodies, with-
out affecting the number of germinal center B cells or
antibody isotype usage. Thus, we have defined distinct
roles of ICOS costimulation mediated by DCs and
plasma B cells in T cell-dependent antibody responses.Results
DC-B7hTg mice overexpress B7h on CD11c +
dendritic cells
To investigate the in vivo roles of B7h expression on
dendritic cells and B cells, both of which can regulate T
cell-dependent antibody responses, we generated trans-
genic mice with lineage-restricted B7h expression. We
targeted the expression of B7h to DCs using a transgenic
expression vector driven by the CD11c promoter [28].
The DC-B7hTg line was selected from founder mice
based on overexpression of B7h on CD11c + cells, and
dendritic cell-specific transgene expression was con-
firmed by analyzing DC-B7hTg mice on the B7h−/− back-
ground to avoid any contribution from endogenous B7h
(Figure 1A). Flow cytometric analysis revealed that B7h
transgene expression in DC-B7hTg mice was restricted
to CD11c+DCs, and was not expressed on either resting
or in vitro-activated B or T cells. Expression of the DC-
B7h transgene was significantly higher than endogenous
B7h on both resting and activated DCs (Figure 1B), indi-
cating that the DC-B7hTg line could be used to study
the potential regulatory role of enhanced B7h expression
on dendritic cells in vivo.
The B-B7h transgene drives B7h expression on activated
B cells
Expression of B7h was also targeted to B cells using a
transgenic expression vector driven by an immunoglobu-
lin heavy chain VH promoter and the intronic Eμ enhan-
cer [29]. Since BCR cross-linking induces substantial
down-regulation of endogenous B7h on B cells [26], we
selected the B-B7hTg line from founder mice based on
enhanced B7h expression on anti-IgM-activated B cells.
To confirm B cell-specific transgene expression, we ana-
lyzed B7h expression on splenocytes from B-B7hTg mice
on the B7h−/− background to avoid any contribution
from endogenous B7h (Figure 1A). Although transgene
expression was restricted to B220+ cells, and was not
expressed on either dendritic cells or resting or activated
T cells, transgene expression on naïve B cells was very
low. Significant transgenic B7h expression, approaching
the level of endogenous B7h on naïve wild-type B cells,
required extended in vitro B cell activation with anti-
IgM antibodies (Figure 1A: 16 hr stimulation; Figure 1C:
3 day stimulation). Thus, the B7h transgene in B-B7hTg
mice was restricted to B cells and was induced after
activation.
The essentially wild-type levels of B7h on naive B-
B7hTg B cells on the B7h+/+ background allowed us to
focus specifically on testing the in vivo significance of
endogenous B7h down-regulation on activated B cells. A
prior study attempting to analyze the reciprocal question
of the in vivo significance of B7.2 induction on activated
B cells employed the analogous approach of generating
Figure 1 Lineage-specific B7h transgene expression on B cells from B-B7hTg mice after activation and on dendritic cells from
DC-B7hTg mice. B7h transgene expression in B-B7hTg and DC-B7hTg mice was assessed by flow cytometry on the B7h−/− background to avoid
contribution from endogenous B7h. B7h staining is shown (solid line) after gating on the indicated cell subsets, with background staining of
B7h−/− controls (dashed line). (A) B7h transgene expression on resting splenocytes was assessed using CD11c, B220, and Thy1 as markers for DCs,
B cells and T cells, respectively. To assess transgene expression on activated B and T cells, purified resting splenic B and T cells were activated for
16 hours with anti-IgM F(ab’)2 or PMA and ionomycin, respectively. (B) B7h and B7.2 expression were examined on splenic CD11c+ dendritic cells
from naive mice, purified CD11c+ dendritic cells derived from bone marrow, and splenic CD11c+ cells purified from mice injected with
Flt3-ligand-expressing B16 cells, either directly ex vivo or after 16 hours of treatment with LPS. For B7.2 analysis, dashed lines represent the
background staining of a non-specific isotype control antibody. (C) B7h staining of purified resting splenic B cells, gated B220+, was assessed
before and after 3 days of stimulation with anti-IgM F(ab’)2. B7h staining of B220
+IgDneg-GL7+Fas+ germinal center B cells and
IgDneg-syndecan-1+B220lo plasma B cells was assessed at day 7 in mice immunized with NP-CGG in alum.
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gene [30]. Interpretation of antibody responses in these
mice, however, was precluded by a severe reduction in
the number of resting naïve B cells that resulted from
the inappropriate expression of B7.2 on resting B cells.
In contrast, both B-B7hTg mice, with restricted B7h
transgene expression on activated B cells, and DC-
B7hTg mice, with restricted B7h transgene expression on
CD11c+DCs, exhibited normal numbers of B220+, CD4+,
CD8+, and CD11c + splenocytes (Additional file 1:Figure S1), consistent with phenotypically normal rest-
ing immune systems.
Endogenous B7h expression is limited on plasma B cells
Although it was known that B cell receptor and IL-4R
activation of B cells led to extinguishment of B7h ex-
pression in vitro [26], the corresponding in vivo expres-
sion of B7h on activated germinal center and plasma B
cell subsets was not known at the time we began our
studies. In wild-type C57Bl6 mice immunized with the T
Larimore et al. BMC Immunology 2012, 13:29 Page 4 of 14
http://www.biomedcentral.com/1471-2172/13/29cell-dependent antigen NP-CGG (4-Hydroxy-3-nitrophe-
nylacetyl hapten conjugated to chicken gamma globulin)in
alum, B7h was highly expressed on B220+IgD+ naïve B
cells and B220+IgDnegGL7+Fas+ germinal center B cells,
but the expression level was dramatically reduced on
IgDnegSyndecan-1+B220lo plasma B cells (Figure 1C). In
contrast, transgene-driven B7h expression in immunized
B-B7hTg mice on the B7h−/− background was barely de-
tectable on naïve and germinal center B cells, but
appeared to be selectively induced on responding plasma
B cells.
The B-B7h transgene drives overexpression of B7h on
activated and plasma B cells in the presence of
endogenous B7h
Having observed induction of B7h expression on B
cells from B-B7hTg mice on the B7h−/− background
after in vitro activation or in vivo differentiation to the
plasma cell lineage, and reduction of B7h expression
on WT B cells under the same conditions, we sought
to determine whether the presence of the B-B7h trans-
gene would lead to overexpression of B7h on activated
and plasma B cells in the presence of endogenous B7h.
To assess B7h expression on activated B cells, we puri-
fied B cells from naïve B7h−/−, B7h+/−, and B-B7hTg
mice on the B7h−/− and B7h+/− backgrounds, cultured
the cells for 72 hours in the presence of B cell stimuli,
and measured cell-surface B7h expression by FACS
(Figure 2A). Endogenous B7h expression was high on
untreated B cells and was reduced after culture with
an activating anti-IgM antibody F(ab’)2, LPS, IL-4, or
CpG oligonucleotide, consistent with previous observa-
tions [26]. Conversely, on the B7h−/− background the
B-B7h transgene was not expressed on untreated cells,
was strongly induced by IgM cross-linking, and was
induced at a low level by culture with LPS or CpG
DNA, but not IL-4. B cells from B-B7hTg mice on the
B7h+/− background expressed B7h on the cell surface
at levels equivalent to non-transgenic controls directly
ex vivo, and activating stimuli led to down-regulation
of B7h expression after culture in vitro. However, the
level of cell-surface B7h after IgM cross-linking was
markedly higher on cells from B-B7hTg mice on the
B7h+/− background compared with anti-IgM-treated B
cells from B7h+/− mice, suggesting that induction of
transgenic B7h expression led to overexpression of B7h
on B cells after BCR-mediated activation, when en-
dogenous B7h expression was limited.
To determine whether the B-B7h transgene led to
overexpression of B7h on plasma B cells in the presence
of endogenous B7h in vivo, we isolated splenocytes
from B7h−/− and B7h+/− mice, as well as B-B7hTg mice
on the B7h−/− and B7h+/− backgrounds, 7 days after
immunization with NP-CGG, and analyzed B7hexpression on B cell subsets by FACS (Figure 2B). On
both B220+IgD+ naïve B cells and B220+IgDnegGL7+CD95+
germinal center B cells, B7h expression was equivalently
high on cells from B7h+/− mice and B-B7hTg mice on the
B7h+/− background, and barely detectable on cells from B-
B7hTg mice on the B7h−/− background, indicating that
the B-B7h transgene did not induce B7h expression in
these subsets. In contrast, IgDnegB220loCD138+ plasma
B cells from B7h+/− mice expressed low levels of cell
surface B7h, while B-B7hTg mice on both the B7h+/−
and B7h−/− backgrounds expressed high levels of B7h,
confirming that the B-B7h transgene was induced on
plasma B cells, leading to overexpression in the pres-
ence of endogenous B7h. These results suggest that
ICOS costimulation might normally be limited by
down-regulation of endogenous B7h expression on
recently-activated B cells and differentiated plasma B
cells, and the observed induction of B7h on activated
and plasma B cells in B-B7hTg mice could be used to
test the functional significance of regulated B7h ex-
pression on wild-type B cells in vivo.
B7h expression on B cells regulates the magnitude of
T cell-dependent antibody responses
B-B7hTg mice and non-transgenic littermates on the
B7h+/+ background were immunized with the T cell-
dependent antigen NP-CGG in alum, and anti-NP serum
antibody concentrations were measured after 7 days by
ELISA (Figure 3A). Total anti-NP IgG, but not anti-NP
IgM responses were significantly increased in B-B7hTg
mice over non-transgenic littermate controls. The in-
crease in total anti-NP IgG responses of B-B7hTg mice
was reflected in all IgG isotypes examined, suggesting
that the level of B7h expression on responding plasma B
cells regulated the overall magnitude of the IgG response
through ICOS costimulation. Investigation of serum
antibody responses on day 14 after immunization
(Figure 3C) confirmed the increase in antigen-specific
antibody concentration in B-B7hTg mice over controls,
while the IgG2a/IgG1 isotype ratio was equivalent to
that seen in wild-type mice, suggesting that plasma B
cell-mediated ICOS signaling did not affect antibody iso-
type usage.
We observed increased production of anti-NP
IgG1 antibodies (as well as other IgG isotypes not
shown) from overnight cultures of splenocytes iso-
lated from B-B7hTg mice on the B7h+/+ background
7 days after immunization, compared with wild-type
controls (Figure 4A). To determine whether this
phenotype resulted from increased plasma cell num-
bers or from increased antibody production per
plasma cell, we measured the number of NP-specific
IgG1-secreting splenocytes by ELISPOT analysis.
Increased numbers of anti-NP antibody-producing
Figure 2 The B-B7h transgene is overexpressed on activated and plasma B cells in the presence of endogenous B7h. (A) Purified B cells
from B7h+/−, B7h−/−, and B-B7hTg mice on the B7h+/− and B7h−/− backgrounds were cultured for 72 hours in the presence of activating stimuli,
and cell surface B7h levels were measured by FACS. Dashed lines represent staining of B7h on B7h−/− cells cultured in the presence of stimuli;
solid lines represent cells cultured without stimuli, and shaded histograms represent cells cultured with stimuli, from mice of the genotypes
shown on the right. (B) Seven days after immunization with NP-CGG, splenocytes from mice with the genotypes indicated in the legend were
analyzed by FACS for cell-surface B7h levels and lineage markers. Naïve B cells were gated B220+IgD+, germinal center B cells were gated B220
+IgDnegGL7+CD95+, and plasma cells were gated IgDnegB220loCD138+.
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mice, but not from DC-B7hTg mice, when compared
to wild-type controls (Figure 4B). Increased plasma
cell numbers in immunized B-B7hTg mice did not
result from an increase in the number of germinal
center B cells that can give rise to antibody-
secreting plasma cells [31], as equivalent numbers of
germinal center B cells were detected by flow cyto-
metry at the peak of the germinal center response
in spleens from both immunized B-B7hTg and DC-
B7hTg mice on the B7h+/+ background, in compari-
son to wild-type controls (Figure 4C). These results
suggest that the number of plasma cells generated
in response to T cell-dependent antigens is con-
trolled in part by the level of ICOS costimulation
provided by plasma cells, as transgenic B7h overex-
pression on this cell type resulted in an increase in
both the number of responding plasma B cells and
the serum concentration of antigen-specific IgG
antibodies.B7h expression on plasma B cells regulates high affinity
antibody production
The primary immune response to NP-CGG immunization
leads to production of low affinity antibody-secreting
plasma cells early in the response (peaking at day 7), while
the germinal center reaction selects for plasma cells se-
creting mutated high-affinity antibodies at later time
points [32,33]. Having observed an increase in total
antigen-specific IgG production in immunized B-B7hTg
mice on the B7h+/+ background over non-transgenic con-
trols on day 7, we wondered whether increased B7h ex-
pression on plasma B cells in these mice also affected the
production of high affinity IgG. We therefore investigated
the affinity maturation of anti-NP IgG responses in trans-
genic and control mice by examining the ratio of high af-
finity anti-NP IgG (IgG binding NP1BSA) to total anti-NP
IgG (IgG binding NP15BSA) by ELISA in sera obtained
21 days after immunization (Figure 5). In comparison to
wild-type B7h+/+ controls, high-affinity NP-specific IgG
responses were defective in B7h−/−mice, consistent with
Figure 3 ICOS costimulation mediated by plasma B cells and DCs selectively regulate the magnitude and isotype usage of antibody
responses. Transgenic mice on the B7h+/+ background and non-transgenic littermate controls were immunized with NP-CGG in alum, and
serum antibody responses were analyzed by ELISA. Relative isotype-specific anti-NP serum antibody concentrations at day 7 are shown for
B-B7hTg (A) and DC-B7hTg (B) mice, compared with wild-type controls. (C) The relative serum concentrations of anti-NP IgG, IgG1, IgG2a, and the
IgG2a/IgG1 ratio are shown at day 14 for transgenic and wild-type mice. Each symbol represents an individual immunized mouse and the mean
of each group is indicated by a solid bar. The data were normalized such that control groups have mean value of 1. Asterisks and p values are
shown where statistical significance (Student’s t test, p < 0.05) was detected between transgenic and control groups. The data are representative
of at least 3 independent experiments.
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affinity NP-specific IgG were increased in B-B7hTg mice
on the B7h+/+ background, but not in DC-B7hTg mice,
when compared with wild-type B7h+/+ controls. Thus,enhanced B7h expression on plasma B cells, but not den-
dritic cells, markedly increased the production of both
total and high affinity anti-NP IgG antibodies after
immunization.
Figure 4 The level of B7h on plasma B cells regulates the number of antibody secreting cells generated by immunization. Transgenic
and control mice on the B7h+/+ background were immunized with NP-CGG and analyzed after 14 days. (A) The relative concentration of anti-NP
IgG1 antibodies in supernatants from overnight splenocyte cultures and in serum were measured by ELISA. Each symbol represents one mouse
and bars indicate the mean of each group. The data were normalized such that the mean of the control group had a value of 1. P values are
shown where statistically significant differences were found between transgenic and control groups. (B) The number of anti-NP IgG1-secreting
splenocytes was determined using an ELISPOT assay. Symbols represent the population mean at each dilution and error bars show the standard
error of the mean for each group. Statistical significance was found between control mice (n = 6) and B-B7hTg mice (n = 5), but not DC-B7hTg
mice (n = 6). (C) The number of B220+IgDneg-GL7+Fas+ germinal center B cells was determined by flow cytometry. Each symbol represents one
mouse and bars indicate the mean of each group. The data are representative of at least 3 independent experiments.
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IgG2a isotype usage
In contrast to our observations in B-B7hTg mice,
increased B7h expression on dendritic cells in DC-
B7hTg mice did not affect the magnitude of IgG
responses. Parallel immunization experiments with DC-
B7hTg mice on the B7h+/+ background and non-transgenic littermate controls revealed no significant dif-
ferences in either total IgG or IgM anti-NP responses
(Figure 3B). Although overall IgG responses were un-
affected, a selective increase in anti-NP IgG2a produc-
tion was observed in DC-B7hTg mice when compared
with wild-type controls, indicating a specific role for



















































































Figure 5 The level of B7h on plasma B cells, but not on
dendritic cells, regulates high-affinity antibody responses to T
cell-dependent antigens. Transgenic B-B7hTg and DC-B7hTg mice
on the B7h+/+ background, and non-transgenic B7h+/+ and B7h−/−
controls were immunized with NP-CGG in alum, and the affinity of
serum anti-NP IgG responses were assessed by ELISA after 21 days.
Total NP-specific IgG (captured with NP15BSA; upper panels),
high-affinity anti-NP IgG (captured with NP1BSA; middle), and the
ratio of high affinity/total NP-specific IgG (lower panels) are shown
relative to wild-type responses. Each symbol represents an individual
mouse and bars indicate the mean of each group. The data were
normalized such that the mean of the wild-type group was equal to
1. P values are shown for comparisons where differences were
statistically significant. The data are representative of three
independent experiments.
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these results, the IgG2a/IgG1 ratio of NP-specific serum
antibodies was also increased in DC-B7hTg mice on the
B7h+/+ background compared with wild-type control
mice 14 days after immunization (Figure 3C).
B7h expression on dendritic cells contributes to germinal
center formation
Studies of knockout mice have demonstrated the re-
quirement of ICOS signaling for germinal center forma-
tion [13-15]. However, the identity of the B7h-expressing
cell type(s) that lead to germinal center formation
through ligation of ICOS on activated T cells have not
been fully defined. To determine whether expression of
B7h on DCs or plasma B cells contribute to germinal
center formation, we crossed DC-B7hTg and B-B7hTg
mice with B7h−/− mice, and examined germinal center
activity both by immunohistochemical analysis of frozen
spleen sections and by flow cytometry 14 days after
immunization (Figures 6A, 6B, and Additional file 2:
Figure S2). Consistent with prior studies of knockout
mice [13-15], PNA+ germinal centers were small and
rare in immunized B7h−/− mice, but large and numer-
ous in immunized B7h+/+ controls. Restoration of B7h
expression on dendritic cells (DC-B7hTg), but not on
plasma B cells (B-B7hTg), partially rescued germinal
center formation in B7h−/− mice, leading to increases in
both the size of germinal centers and the number of
germinal center B cells, suggesting that ICOS signaling
in T cells mediated by contact with B7h-expressing
DCs, but not plasma B cells, contributes to germinal
center formation.
Both the total amount of antibody produced and
the affinity of the observed antibody responses, as
reflected by the ratio of NP1BSA-binding/NP15BSA-
binding serum IgG at day 21, were dramatically
reduced in B7h−/− mice compared with B7h+/+ controls
(Figure 6B). While B7h expression on either plasma B
cells or DCs in mice on the B7h−/− background was
sufficient to restore total IgG responses to wild-type
levels, the affinity of the antibody responses in these
mice did not reach the level observed in B7h+/+ mice.
However, partial rescue of germinal center formation
in B7h−/− mice by expression of B7h on DCs (DC-
B7hTg), but not on plasma B cells (B-B7hTg), was cor-
related with an increase in the affinity of the antibody
response over B7h−/− controls, suggesting that augmen-
tation of germinal center formation by DC-mediated
ICOS costimulation lead to increased antibody affinity
maturation.
To confirm our observations in transgenic mice on the
B7h+/+ background, we also assessed antibody isotype
usage in transgenic mice on the B7h−/− background by










































































































































Figure 6 B7h expression on DCs, but not plasma B cells, contributes to germinal center formation and enhances IgG2a isotype usage.
Transgenic mice on the B7h−/− background were immunized with NP-CGG in alum, and analyzed after 14–21 days. (A) Splenic cryosections were
analyzed by immunohistochemistry on day 14 to reveal PNA+ germinal centers (indicated by arrow). Images are representative of larger fields
shown in Additional file 2: Figure S2. Original total magnification was 64X. (B) The number of germinal center B cells measured by flow
cytometry, the relative cross-sectional area of germinal centers determined by imaging, and serum anti-NP IgG responses measured by ELISA at
day 14 are shown. The relative affinities of serum anti-NP antibody responses were measured by the ratio of NP1/NP15-binding serum IgG on day
21. (C) The ratios of NP-specific IgG2a and IgG1 to total NP-specific IgG in serum on day 14, determined by ELISA, are shown. For ELISA and flow
cytometry data, each symbol represents an individual immunized mouse. For GC size analysis, each symbol represents an individual germinal
center. The mean of each group is indicated by a solid bar, and p values are shown where significance was detected (Student’s t test, p < 0.05)
between the B7h−/− group and transgenic or B7h+/+ groups. For ELISA data, the mean values from control B7h−/− groups were set to a value of
1. The data are representative of three independent experiments.
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selectively increased isotype switching to IgG2a,
reflected by an increase in the NP-specific IgG2a/IgG
ratio, but not the IgG1/IgG ratio, over B7h−/− controls
(Figure 6C). In contrast, antibody isotype usage was
equivalent between B-B7hTg mice on the B7h−/− back-
ground and non-transgenic controls. Thus, our resultssuggest ICOS costimulation mediated by DCs, but not
plasma B cells, contributes to germinal center formation
and selectively enhances IgG2a isotype usage.
Discussion
Analyses of both ICOS−/− and B7h−/− mice have demon-
strated the critical requirement of ICOS costimulation
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switching, affinity maturation, and antibody production
in T cell-dependent antibody responses [1,7,13,14]. How-
ever, knockout mice exhibit defects at multiple stages of
T cell-dependent antibody responses, ICOS costimula-
tion can have diverse effects on immune responses de-
pending on the context of signaling, and B7h is
expressed on multiple antigen presenting cell types
involved in antibody responses. Thus, studies of knock-
out mice could not dissect the potential cell type-
specific roles of B7h expression on antigen presenting
cells in T cell-dependent antibody responses. We have
extended previous studies using transgenic mice with
lineage-restricted B7h expression to define selective roles
for ICOS costimulation mediated by DCs and plasma B
cells in the context of antibody responses.
Our results demonstrate that endogenous B7h expres-
sion is high on naïve and germinal center B cells, but is
reduced on activated and plasma B cells, and transgenic
induction of B7h expression on activated and plasma B
cells in B-B7hTg mice enhances the number of antibody-
secreting cells produced in response to T cell-dependent
antigens. The observed expression pattern of the B-B7h
transgene may most likely be explained as a result of the
use of an immunoglobulin promoter in place of the en-
dogenous B7h promoter sequences to drive transgene
expression, as the immunoglobulin promoter is upregu-
lated in plasma B cells, and possibly also by insertion of
the transgene at a genomic location that is available for
transcription only in activated B cells. The latter possi-
bility could potentially be problematic if the transgene
insertion disrupted an endogenous gene that is import-
ant for B cell function. Fortunately, we did not observe
any defects in B cell function in B-B7hTg mice in vitro
or in vivo, leading us to conclude that such a disruption
is unlikely to have occurred in this case.
While we observed induction of B7h expression in B-
B7hTg B cells after BCR cross-linking in vitro, we were
unable to specifically identify analogous recently acti-
vated B cells in vivo in our system, as the frequency of
NP-reactive B cells in naïve mice is very low, and the
low affinity of primary naïve B cells for NP precluded
direct identification of NP-specific cells by FACS based
on NP binding in the first few days after immunization
in our hands. Although we could not directly measure
B7h expression levels on recently activated B cells
in vivo, our in vitro results suggest that the B-B7h trans-
gene may lead to overexpression of B7h on these cells in
the first 2–3 days, a time frame in which they interact
with cognate activated T cells in interfolicular regions
[34,35]. Thus, it is possible that increased ICOS costi-
mulation in T cells interacting with responding follicular
B cells in the first 2–3 days after immunization contribu-
ted to the increased antibody responses in B-B7hTgmice. However, it is not clear how ICOS signaling in
early cognate B-T interactions could augment the levels
of both pre-germinal center low affinity and post-
germinal center high affinity antibody production with-
out affecting the number of germinal center B cells.
In addition to expression on in vitro-activated B cells,
the B-B7h transgene consistently led to dramatic overex-
pression of B7h on responding plasma B cells in vivo,
and an expansion of these cells in comparison to non-
transgenic control mice. The correlation between B7h
overexpression on plasma cells and cellular expansion of
plasma cells in B-B7hTg mice suggests that differentiated
plasma B cells make contact with ICOS-expressing acti-
vated T cells, and this interaction regulates the magni-
tude of antibody responses based in part on the level of
B7h expression on B cells, which influences the strength
of ICOS signaling in cognate T cells. This putative
plasma cell-T cell interaction could potentially occur be-
tween Tfh cells and newly differentiated plasma cells in
germinal centers, and/or between activated Th cells and
plasma cells that co-localize in peri-arteriolar lymphoid
sheaths (PALS) in lymph nodes and spleen [24]. The
observed increase in the number of antibody-secreting
cells in B-B7hTg mice at day 7 implies that plasma cell-T
cell interactions that regulate antibody responses can
likely occur outside of germinal centers, as the majority
of antibody secreting cells at this early time point are
not germinal-center derived [33].
ICOS costimulation in T cells is dynamically regulated
on multiple levels. A previous study generated trans-
genic mice that overexpress ICOS on all T cells [36], and
made the counterintuitive finding that antibody and ger-
minal center responses were reduced in ICOS transgenic
mice, as a result of the increased clipping of B7h from
the cell surface of APCs after contact with ICOS [27].
The resulting reduction of B7h expression on APCs in
ICOS transgenic mice caused a reduction of ICOS costi-
mulation in vivo compared with WT mice, leading to
defects in B cell responses to T cell-dependent antigens.
In addition to ICOS contact, previous in vitro studies
have shown that IL4-R and antigen receptor signals re-
duce cell surface B7h levels on B cells through transcrip-
tional and post-transcriptional mechanisms, while the
addition of CD40, TLR7/8 and/or TLR9 signals can limit
the extent of B7h downregulation after activation or ICOS
contact, causing a relative increase in ICOS co-stimulation
in cognate T cells [26,27]. In our B-B7hTg model the B7h
transgene was induced on activated B cells as a result of
the transgenic promoter, leading to an increase in cell sur-
face B7h levels on activated B cells, which was most not-
able in vivo on differentiated plasma B cells. Ultimately
this increased cell surface B7h expression led to expansion
of plasma cells in vivo, presumably through increased
ICOS co-stimulation in cognate T cells.
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tude of antibody responses in part by modulating B7h
levels in response to multiple signaling pathways. In
this model, physiological settings where endogenous
B7h expression on B cells is enhanced or stabilized
during antibody responses, such as by CD40 or TLR9
signaling, are predicted to lead to increased class-
switched antibody production. Conversely, the results
of studies of ICOS transgenic mice suggest that stimuli
that lead to an increase in ICOS expression on T cells
may counter-intuitively reduce antibody responses
through increased clipping of B7h from the cell surface
of cognate APCs.
Our results have potential practical implications for
the improvement of vaccination strategies, as they
demonstrate that ICOS signaling is not only required
for many aspects of T cell-dependent antibody
responses, but that the strength of ICOS signaling,
which is controlled in part by changing levels of B7h
on APCs, can modulate antibody responses in the right
context. Hence, vaccination strategies that increase
ICOS costimulation either directly with ICOS agonists,
or indirectly by attempting to stabilize B7h expression
on B cells through CD40 or TLR signaling, may be
useful to augment the magnitude of vaccine-induced
high affinity antibody responses. Conversely, ICOS
blockade may be a useful strategy for reducing the ex-
pansion of plasma cells secreting pathogenic antibodies
in the setting of B cell-mediated autoimmunity [37,38].
Interactions between plasma B cells and ICOS+ T cells
in the kidneys of lupus patients have been correlated
with exaggerated plasma cell generation and patho-
genic antibody production [39]. Our data suggest that
the level of ICOS signaling in such interactions can
regulate the plasma cell response, and blocking ICOS
costimulation in this setting may be a useful thera-
peutic strategy to reduce the production of auto-
antibodies.
Our results show that overexpression of B7h on acti-
vated and plasma B cells led to an increase in high-
affinity IgG production 21 days after immunization
(Figure 5). In this experiment, although a statistically sig-
nificant difference in high-affinity NP1-binding IgG
could be detected between B7h+/+ and B7h−/− mice, the
difference in total NP15-binding IgG was not significant.
This was surprising, as numerous studies have reported
defects in class-switched antibody production in B7h−/−
and ICOS−/− mice or after ICOS blockade in WT mice
[7,14,15,40]. However, several studies showed a decrease
in IgG1, but not IgG2a production, after primary
immunization [7,40], suggesting that all isotypes may not
be equivalently affected, and the extent of the observed
differences vary between studies using different immuno-
gens, adjuvants, and timing of sample collection [14]. Inthe case of the experiment shown in Figure 5, we may have
failed to detect a difference between B7h+/+ and B7h−/−
responses because we measured all IgG isotypes together,
and took blood samples at day 21 for the purpose of
measuring affinity maturation, in contrast to previous
reports that show differences specifically for the IgG1
isotype, at 7 and 14 days after immunization. In fact,
in a similar experiment measuring total NP15-binding IgG
at day 14, we did detect a statistically significant difference
between B7h+/+ and B7h−/− animals (Figure 6B), suggest-
ing that while IgG responses in B7h−/− mice are initially
deficient, at later time points total antigen-specific IgG in
immunized B7h−/− mice may reach wild-type levels, al-
though high-affinity (NP1-binding) antibody responses
were deficient as a result of limited germinal center ac-
tivity in knockout mice.
Initial studies reported Th1 polarization [16], reduced
IL-4 production [15,41], and inhibition of Th2-mediated
lung mucosal inflammation [40,42] in the absence of
ICOS signaling, suggesting a role for ICOS in Th2
polarization. Additional studies have paradoxically
shown amelioration of Th1-mediated allograft rejection
[43], EAE [25,44], and diabetes [45] in the absence of
ICOS signaling, as well as enhancement of Th1-driven
IgG2a production by an activatory B7h-Ig fusion protein
[9]. Our results suggest these observations are not
contradictory, but rather the outcome of ICOS signaling
in activated T cells is highly dependent on the context of
B7h-ICOS interactions, as B7h expressed on dendritic
cells, but not plasma B cells, can specifically enhance
Th1-driven IgG2a responses, while B7h expression on
plasma B cells increases IgG production of all isotypes.
This may in part reflect the fact that responding DCs
and plasma B cells can localize to separate micro-envir-
onments, and potentially interact with CD4+ T cells in
different states of differentiation that regulate distinct
aspects of antibody responses.
In addition to the effect on antibody isotype
switching, we show that B7h expression on dendritic
cells also contributes to germinal center formation,
which leads to antibody affinity maturation. However,
the number of responding germinal center B cells in
mice that only express B7h on DCs (DC-B7hTg x
B7h−/−) was reduced in comparison to wild-type B7h+/+
mice (Figure 5b), suggesting that additional ICOS costi-
mulation mediated by other cell types is necessary for op-
timal germinal center responses and antibody affinity
maturation. Since ICOS expression is high on Tfh cells in
germinal centers and endogenous B7h expression is high
on germinal center B cells, it is likely that germinal center
B cell-mediated ICOS signaling in Tfh cells also contri-
butes to the size and dynamics of germinal centers and
the extent of antibody affinity maturation in wild-type
mice.
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In summary, ICOS costimulation mediated by plasma B
cells and dendritic cells have distinct functions in T cell-
dependent antibody responses. While ICOS signaling in
T cells mediated by B7h-expressing DCs contributes to
germinal center formation and can affect antibody iso-
type usage, the B7h expression level on plasma B cells
regulates the overall magnitude of antibody responses to
T cell-dependent antigens without affecting antibody iso-
type usage or the number of germinal center B cells. The
latter result suggests a control point that may be useful
for enhancement of vaccine-induced antibody responses,
or reduction of pathogenic antibody responses, through
modulation of ICOS signaling.
Methods
Transgenic mice
All work involving animals was performed in accordance
with the NIH Office of Laboratory Animal Welfare guide-
lines and was approved by the UC Berkeley Institutional
Animal Care and Use Committee.
The construct driving B7h expression in B-B7hTg mice
was created by modifying an existing vector that utilizes
an immunoglobulin VH promoter and enhancer for
cDNA expression in B cells [29], in which transcription
is driven by a 0.9 kb XbaI fragment containing the in-
tronic Eμ enhancer and a 1.4 kb fragment of the
VH17.2.25 promoter ending at a SalI cloning site at pos-
ition +38, upstream of the Kozak ATG sequence at +47
[46]. A SalI-NotI blunted B7h-GFP cDNA insert, encod-
ing for a previously described B7h-GFP fusion protein
[5], where the N terminus of GFP was fused to the C
terminal end of the cytoplasmic tail of full-length B7h,
was sub-cloned into the SalI site of the vector, which
was additionally modified to replace the SV40 splice and
polyA sequences with a BamHI-NotI insert containing
the human growth hormone (hGH) minigene from the
p1017-lck expression vector plasmid [47]. A 6.9 kb NotI
insert lacking plasmid vector sequences was microin-
jected into (CBA X B6)F1 embryos. The B-B7hTg line
utilized in these studies was subsequently backcrossed to
B6 mice for at least 10 generations.
The construct driving B7h expression in DC-B7hTg
mice was created by modifying an existing transgenic vec-
tor designed for cDNA expression in DCs driven by the
CD11c promoter upstream of the rat β-globin splice site
and polyA signal sequence [28]. A blunted 2.5 kb B7h-
IRES-GFP cDNA insert, excised from an MSCV-IRES-
GFP retroviral vector [27,48] expressing the B7h cDNA
[5], was then sub-cloned into a PmeI site that was intro-
duced into the EcoRI cloning site of the vector by anneal-
ing overlapping primers 5— AATTGTTTAAAGCCGG-
3′ and 5′-ATTCCGGGTTTAAAC-3′ to the EcoRI-
digested vector. A 9 kb NotI-XhoI insert lacking plasmidvector sequences was then microinjected into B6
embryos. The DC-B7hTg line reported here was selected
for high B7h expression on CD11c+ cells. Transgenic lines
were crossed onto B7h−/− mice on the C57Bl6/J back-
ground, a generous gift of Dr. Tak Mak [7], and were
maintained on the C57Bl6/J background.
Immunization
NP-OsU (Biosearch Technologies) was conjugated to
chicken gamma globulin (CGG; Jackson Immunore-
search) or bovine serum albumin (BSA; Sigma) to form
NP-CGG or NP-BSA at different conjugation ratios that
were confirmed by spectroscopy. Age-matched groups
of mice were immunized intraperitoneally in the lower
right quadrant with 100 μg NP10CGG precipitated in
alum, in a final volume of 100 μL phosphate-buffered
saline (PBS). Levels of NP-specific antibodies in sera
were detected using ELISA plates (Costar) coated with
5 μg/mL NP15BSA or NP1BSA in PBS overnight at 4°C,
and isotype-specific HRP-conjugated anti-mouse IgG or
IgG1 (Southern Biotech), or biotinylated anti-mouse
IgG2a, IgG2b, IgG3 or IgM (Pharmingen) detection
reagents. Plates were developed with streptavidin-
conjugated HRP and ABTS substrate (Pharmingen), and
absorbance at 405 nm of a two-fold dilution series in
the linear range was used to calculate relative amounts
of antiNP antibodies. ELISPOT analysis of antibody
producing cells was conducted using MultiScreen-IP
plates (Millipore) coated with 50 μg/mL NP15BSA. Puri-
fied splenocytes were serially diluted in duplicate onto
blocked washed plates in lymphocyte media and cul-
tured overnight at 37°C. NP-specific spots were detected
with an HRP-conjugated goat anti-mouse IgG1 antibody
(Southern Biotech), developed using the AEC chroma-
gen kit (Sigma), and ELISPOTs were counted using a
dissecting microscope.
Flow cytometry and cells
Immature dendritic cells were derived by isolating bone
marrow from the long bones of the legs and culturing
in IMDM containing 10% FBS, 1% Pen/Strep, and
500 ng/mL GM-CSF (R&D Systems) for 7 days. Splenic
dendritic cells were enriched in some experiments by
injecting mice subcutaneously with an FLT3L-secreting
B16 tumor cell line 14–21 days before analysis. Dis-
sected spleens were injected with 400 U/mL collage-
nase in PBS to disaggregate splenocytes, and dead cells
were removed by density gradient centrifugation prior
to isolation of DCs with anti-CD11c microspheres
(Miltenyi Biotec). Dendridic cells were activated in
some experiments by culture for 16 hours in the pres-
ence of 1 μg/mL LPS (Sigma). B and T cells were puri-
fied from mice as described previously [26] and
activated by culture in 96-well plates at 10 X 106 cells/
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anti-mouse-IgM F(ab’)2 (Jackson Immunoresearch),
250 nm PMA (Sigma) and 2 μM Ionomycin (Sigma),
10 μg/mL LPS (Sigma), 5 μg/mL CpG oligonucleotide
1826 (5′-TCCATGACGTTCCTGACGTT-3′), or 5 ng/mL
IL-4 (R&D Systems).
Splenocyte suspensions or purified cells were stained
for flow cytometric analysis as described [27] using the
following reagents: IgD-FITC (eBioscience), B220-
PETexasRed (Pharmingen), Fas-PECy7 (Pharmingen),
syndecan-1-APC (Pharmingen), CDllc-PE (Caltag),
CD11c-PECy7 (Pharmingen), B7.2-PE (Pharmingen),
purified rat IgM anti-GL7 (eBioscience) followed by
anti-rat IgM-PE secondary (eBioscience), and 22D7
hamster anti-mouse B7h [13] followed by streptavidin-
PE (eBioscience) or streptavidin-PECy5 (Pharmingen).
For cell surface B7h analysis, splenocytes were cultured
for 2 hours at 37°C in lymphocyte media and blocked
with 220 μg/mL Syrian hamster gamma globulin (Jackson
ImmunoResearch). Germinal center B cells were gated
as B220+IgDnegGL7+Fashi, plasma cells were IgDneg-
Syndecan+B220lo, naïve B cells were B220+IgD+, and
dendritic cells were CD19negCD11c+.
Immunohistochemistry
Spleens from immunized mice were snap frozen in
OCT, and glass slides with microtome sliced issues sec-
tions cut to 5–7 μm were stained with biotinylated pea-
nut agglutinin (PNA) in PBS. PNA+ germinal centers
were revealed using an ABC Elite staining kit with DAB
substrate (Vector labs). Slides were imaged on a Zeiss
NeoLumar stereomicroscope using a 0.8x, 80 mm ob-
jective at 64X total magnification. Images were acquired
with a MicroPublisher 3.3 Qimaging camera and QIma-
ging software; contrast of final images was adjusted uni-
formly to all images using Adobe Photoshop.
Statistical analysis
Statistical significance between groups of mice was eval-
uated using Student’s t test (one-tailed, two sample, un-
equal variance). All analyses returning a p value < 0.05
are labeled. Analyses where no p value is shown
returned p > 0.05.
Additional files
Additional file 1: Figure S1. Normal lymphocyte populations in resting
B7hTg mice. Splenic lymphocyte populations were assessed in resting B-
B7hTg and DC-B7hTg animals on the B7h+/+ background by flow
cytometry. The number of lineage marker positive cells is plotted as a
percentage of total splenocytes, with representative gating shown on the
left. Each symbol represents an individual animal, with the mean of each
group represented by a solid bar.
Additional file 2: Figure S2. Defective germinal center formation is
restored by expression of B7h on CD11c+ dendritic cells, but not onplasma B cells. Splenic cryosections from immunized mice at day 14 were
analyzed by immunohistochemistry to detect PNA+ germinal centers.
Images correspond to data presented in Figure 5. Original magnification
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